101. MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer
- Author
-
Elena Geuna, Enrico Berrino, Salvatore Ribisi, Anna Maria Nuzzo, Umberto Miglio, Enzo Medico, Danilo Galizia, Filippo Montemurro, Annalisa Petrelli, Sara Erika Bellomo, Silvia Giordano, Ivana Sarotto, Maria Rosaria Di Virgilio, Paola Sgandurra, Tiziana Venesio, Paolo Provero, Franziska Kubatzki, Riccardo Ponzone, Furio Maggiorotto, and Anna Sapino
- Subjects
Hepatocyte Nuclear Factor 3-alpha ,Oncology ,Cancer Research ,medicine.medical_specialty ,Breast Neoplasms ,Disease ,lcsh:RC254-282 ,Breast cancer ,luminal breast cancer ,Internal medicine ,medicine ,Humans ,Endocrine system ,Prospective Studies ,Prospective cohort study ,Original Research ,Insulin-like growth factor 1 receptor ,business.industry ,endocrine therapy ,Letrozole ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,miR-100 ,MicroRNAs ,prognosis ,response prediction ,Female ,FOXA1 ,business ,Tamoxifen ,medicine.drug - Abstract
Purpose Overexpression of miR-100 in stem cells derived from basal-like breast cancers causes loss of stemness, induction of luminal breast cancer markers and response to endocrine therapy. We, therefore, explored miR-100 as a novel biomarker in patients with luminal breast cancer.Methods miR-100 expression was studied in 90 patients with oestrogen-receptor-positive/human-epidermal growth factor receptor 2-negative breast cancer enrolled in a prospective study of endocrine therapy given either preoperatively, or for the treatment of de novo metastatic disease. Response was defined as a Ki67 ≤2.7% after 21±3 days of treatment. The prognostic role of miR-100 expression was evaluated in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas (TCGA) breast cancer datasets. Additionally, we explored the correlation between miR-100 and the expression its targets reported as being associated with endocrine resistance. Finally, we evaluated whether a signature based on miR-100 and its target genes could predict the luminal A molecular subtype.Results Baseline miR-100 was significantly anticorrelated with baseline and post-treatment Ki67 (p
- Published
- 2020